Despite showing promise in phase 2 trials, new results from a randomized phase 3 [ immunotherapy in mesothelioma ] trial are disappointing in a tumor type that remains a major killer. In patients with malignant pleural mesothelioma (MPM) who had progressed after first-line chemotherapy, … More
Main Navigation Menu
➤ Pharmaceutical Drug Injury Lawsuits
➤ Asbestos and Mesothelioma Claims
➤ Benzene Diseases and Cancers Claims
➤ GenX Water Contamination Cancer Cases
➤ Breast Implants Lymphoma Cancer Cases
➤ Free Case Evaluation by Lawyer Tom Lamb
➤ About the Law Offices of Thomas J. Lamb
➤ Frequently Asked Questions (FAQs)
➤ Medical Records Copying Cost Laws
➤ Client Resources: Legal, Medical, and More
➤ Collection of Articles by Our Law Firm
Please know that you can use our Quick Contact Form to tell us a bit about your case.
Recent Articles
Uloric Increased Risk of Patient Cardiovascular Deaths, Says Health Canada
Based on the results of the CARES study, Health Canada mandated an Uloric label change in early November 2019 which warns about an increased risk of Uloric-related cardiovascular deaths. Uloric is now only approved for use in Canada as a treatment “to lower serum uric acid levels in patients with … More
CD70 Expression Correlates With a Worse Prognosis in Malignant Pleural Mesothelioma Patients
Diffuse malignant mesothelioma of the pleura (MPM) is a highly aggressive tumour that typically is associated with short survival. CD70 and CD27 belong to the tumour necrosis factor (TNF) and the TNF receptor (TNFR) superfamily, respectively. Under physiological conditions, the tightly regulated … More
Secretome of pleural effusions associated with non-small cell lung cancer (NSCLC) and malignant mesothelioma: therapeutic implications
Introduction: We compared the secretome of metastatic (non-small cell lung cancer (NSCLC)) and primary (mesothelioma) malignant pleural effusions, benign effusions and the published plasma profile of patients receiving chimeric antigen receptor T cells (CAR-T), to determine factors unique to … More
Xeljanz Should Be Used With Caution In Patients At High Risk Of Blood Clots
There is a new Xeljanz drug safety warning about an increased risk of blood clots resulting in pulmonary embolism (PE) and deep vein thrombosis (DVT). From this PDF document, “Xeljanz to be used with caution for all patients at high risk of blood clots”, issued in October 2019 by the European … More
Keytruda Survival Benefits Similar to Chemo for Relapsed Mesothelioma, Phase 3 Trial Finds
Treatment with the immunotherapy Keytruda (pembrolizumab) appears to be as effective as conventional chemotherapy for treating malignant pleural mesothelioma patients who relapse after one course of platinum-based chemotherapy, data from a Phase 3 trial show. Although more of these advanced … More